•  
  •  
  •  
  •  

2026-08-12 20:34:17

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  INE068V01023

Stock Report

  • Gland Pharma Announces Strategic CDMO Partnership with a Global Pharmaceutical Company
  • Gland Pharma Ltd receives tentative approval from USFDA
  • Gland Pharma Limited announces resignation of CEO
  • Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Gland Pharma receives approval for Vasopressin in 5% Dextrose RTU Injection
  • Gland Pharma receives approval for Norepinephrine Bitartrate in 5% Dextrose Injection Bags
  • Gland Pharma receives approval from USFDA for Cangrelor for Injection 50 mg/vial
  • Gland Pharma Ltd receives GMP compliance from Danish Medicines Agency
  • Gland Pharma Ltd receives EIR from US FDA for JNPC Facility, Visakhapatnam
  • Gland Pharma Receives Approval for Angiotensin II Acetate Injection
  • Gland Pharma receives approval from USFDA for Latanoprostene Bunod Opthalmic Solution
  • Gland Pharma receives approval for Acetaminophen Injection
  • USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit
  • ANSM Inspection at Cenexi's Fontenay Manufacturing Facility
  • Gland Pharma receives approval for Phytonadione Injection Emulsion
  • Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005% (2.5 mL Fill)
  • Surprise USFDA inspection at Gland Pharma Limited's Dundigal Facility
  • Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution
  • Srinivas Sadu appointed as Executive Chairman and CEO of Gland Pharma Ltd
  • Gland Pharma receives approval for Edaravone Injection
  • Gland Pharma receives approval for Plerixafor for Injection
  • Gland Pharma receives approval for Cetrorelix Acetate for Injection
  • Gland Pharma receives approval for Eribulin Mesylate Injection
  • Gland Pharma Ltd receives EIR from USFDA for Pashamylaram Facility at Hyderabad

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025